Value of serum anti-mullerian hormone in the diagnosis of polycystic ovary syndrome
Nội dung chính của bài viết
Tóm tắt
Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting fertility, with diagnostic challenges due to variability in traditional markers like the LH/FSH ratio. This retrospective case-control study aimed to assess the diagnostic performance of anti-Müllerian hormone (AMH) compared to the LH/FSH ratio in women undergoing infertility evaluation at Dong Do Hospital. A total of 178 PCOS cases and 422 controls were identified using the Rotterdam 2003 criteria. Serum levels of AMH, LH, FSH, and testosterone were measured. Women with PCOS showed significantly higher AMH levels than controls (median 7.65 vs. 3.17 ng/mL, p < 0.001). Receiver operating characteristic analysis revealed AMH had excellent diagnostic accuracy (AUC = 0.911), with a cutoff of 5.445 ng/mL yielding 84.8% sensitivity and 82.5% specificity. Multivariable logistic regression confirmed AMH as an independent predictor of PCOS (OR = 1.964, p < 0.001), along with LH/FSH ratio, testosterone, and BMI. Age was not a significant factor. AMH demonstrated superior diagnostic utility over the LH/FSH ratio, highlighting its potential as a reliable biomarker for PCOS diagnosis.
Chi tiết bài viết
Từ khóa
Anti-Müllerian hormone (AMH), Polycystic ovary syndrome (PCOS), LH/FSH ratio, Diagnostic value
Tài liệu tham khảo
2. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. Aug 2 2023;189(2):G43-G64. doi:10.1093/ejendo/lvad096
3. Rosenfield RL. The Diagnosis of Polycystic Ovary Syndrome in Adolescents. Pediatrics. Dec 2015;136(6):1154-65. doi:10.1542/peds.2015-1430
4. Fleming R, Seifer DB, Frattarelli JL, et al. Assessing ovarian response: antral follicle count versus anti-Mullerian hormone. Reprod Biomed Online. Oct 2015;31(4):486-96. doi:10.1016/j.rbmo.2015.06.015
5. van Disseldorp J, Lambalk CB, Kwee J, et al. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod. Jan 2010;25(1):221-7. doi:10.1093/humrep/dep366
6. Pigny P, Merlen E, Robert Y, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. Dec 2003;88(12):5957-62. doi:10.1210/jc.2003-030727
7. Yen SS, Vela P, Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab. Apr 1970;30(4):435-42. doi:10.1210/jcem-30-4-435
8. Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab. Jul 1997;82(7):2248-56. doi:10.1210/jcem.82.7.4105
9. Evliyaoglu O, Imohl M, Weiskirchen R, et al. Age-specific reference values improve the diagnostic performance of AMH in polycystic ovary syndrome. Clin Chem Lab Med. Jul 28 2020;58(8):1291-1301. doi:10.1515/cclm-2019-1059
10. Le MT, Le VNS, Le DD, et al. Exploration of the role of anti-Mullerian hormone and LH/FSH ratio in diagnosis of polycystic ovary syndrome. Clin Endocrinol (Oxf). Apr 2019;90(4):579-585. doi:10.1111/cen.13934
11. Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. Jan 2004;81(1):19-25. doi:10.1016/j.fertnstert.2003.10.004
12. Aslan K, Tunali A, Tellioglu I, Kasapoglu I, et al. Age-stratified analysis of anti-Müllerian hormone (AMH) levels and the prevalence of diminished ovarian reserve in a population of 22,920 women aged 18–45: a retrospective study. Reproductive Biomedicine Online. 2024;49(Suppl):37–38. doi:10.1016/j.rbmo.2024.104549
13. Choi R, Lee SG, Lee EH. Reference intervals of anti-Mullerian hormone in Korean women. J Clin Lab Anal. Sep 2022;36(9):e24525. doi:10.1002/jcla.24525
14. Iliodromiti S, Kelsey TW, Anderson RA, et al. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab. Aug 2013;98(8):3332-40. doi:10.1210/jc.2013-1393
15. van der Ham K, Laven JSE, Tay CT, et al. Anti-mullerian hormone as a diagnostic biomarker for polycystic ovary syndrome and polycystic ovarian morphology: a systematic review and meta-analysis. Fertil Steril. Oct 2024;122(4):727-739. doi:10.1016/j.fertnstert.2024.05.163
16. Hyldgaard J, Bor P, Ingerslev HJ, et al. Comparison of two different methods for measuring anti-mullerian hormone in a clinical series. Reprod Biol Endocrinol. Sep 22 2015;13:107. doi:10.1186/s12958-015-0101-5
17. Vagios S, James KE, Sacha CR, et al. A patient-specific model combining antimullerian hormone and body mass index as a predictor of polycystic ovary syndrome and other oligo-anovulation disorders. Fertil Steril. Jan 2021;115(1):229-237. doi:10.1016/j.fertnstert.2020.07.023
18. Ahmed N, Batarfi AA, Bajouh OS, et al. Serum Anti-Mullerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms. Diagnostics (Basel). Oct 1 2019;9(4)doi:10.3390/diagnostics9040136
19. Khan S GR, Naz S, Gul N, et al. The significance of anti-Müllerian hormone in the identification of polycystic ovarian syndrome among Pakistani women. J Soc Obstet Gynaecol Pak. 2023;13(3):181-185.
20. Wang L, Luo M, Yu X, et al. Assessing the clinical diagnostic value of anti-Mullerian hormone in polycystic ovarian syndrome and its correlation with clinical and metabolism indicators. J Ovarian Res. Apr 10 2024;17(1):78. doi:10.1186/s13048-024-01405-4